

BAY 2666605

Chemical Properties


CAS No. : 2275774-60-0

Formula: C₁₇H₁₂F₄N₂O₂

Molecular Weight: 352.28

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	BAY 2666605 is an orally active inhibitor of PDE3A (IC ₅₀ = 87 nM) and PDE3B (IC ₅₀ = 50 nM) with noted anticancer effects.
Targets(IC ₅₀)	PDE
In vitro	BAY 2666605 inhibits brain cancer(glioma, more specifically glioblastoma, astrocytoma), breast cancer (ductal carcinoma and adenocarcinoma), cervical cancer, AML(erythroleukemia), lung cancer(NSCLC adenocarcinoma and SCLC), skin cancer (melanoma), esophagus cancer (squamous cell carcinoma), ovarian cancer, (teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer[1].
In vivo	In murine xenotransplantation models of human cancer, BAY 2666605 (5 mg/kg; p.o) exhibits anti-tumor efficacy[1].

Solubility Information

Solubility	DMSO: 245 mg/mL (695.47 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8387 mL	14.1933 mL	28.3865 mL
5 mM	0.5677 mL	2.8387 mL	5.6773 mL
10 mM	0.2839 mL	1.4193 mL	2.8387 mL
50 mM	0.0568 mL	0.2839 mL	0.5677 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Manuel ELLERMANN, et al. Dihydrooxadiazinones. WO2019025562A1.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481